Ngam Advisors LP Has Cut By $2.71 Million Its Wpp Plc (WPPGY) Stake; Infinity Pharmaceuticals (INFI) Sentiment Is 0.63

December 8, 2017 - By Peter Erickson

Ngam Advisors Lp decreased Wpp Plc (WPPGY) stake by 27.49% reported in 2017Q2 SEC filing. Ngam Advisors Lp sold 25,826 shares as Wpp Plc (WPPGY)’s stock declined 4.95%. The Ngam Advisors Lp holds 68,134 shares with $7.18 million value, down from 93,960 last quarter. Wpp Plc now has $21.03 billion valuation. The stock increased 0.97% or $0.81 during the last trading session, reaching $84.43. About 113,982 shares traded. WPP plc (NASDAQ:WPPGY) has declined 2.02% since December 8, 2016 and is downtrending. It has underperformed by 18.72% the S&P500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $100.41 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Analysts await Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report earnings on March, 13. They expect $-0.24 earnings per share, up 47.83% or $0.22 from last year’s $-0.46 per share. After $-0.14 actual earnings per share reported by Infinity Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 71.43% negative EPS growth.

Bvf Inc Il holds 1.92% of its portfolio in Infinity Pharmaceuticals, Inc. for 7.87 million shares. Element Capital Management Llc owns 221,738 shares or 0.07% of their US portfolio. Moreover, Orbimed Advisors Llc has 0.05% invested in the company for 3.25 million shares. The Pennsylvania-based Tfs Capital Llc has invested 0.05% in the stock. Pinnacle Associates Ltd, a New York-based fund reported 1.25 million shares.

The stock increased 15.79% or $0.27 during the last trading session, reaching $1.98. About 3.64 million shares traded or 36.94% up from the average. Infinity Pharmaceuticals, Inc. (INFI) has declined 60.96% since December 8, 2016 and is downtrending. It has underperformed by 77.66% the S&P500.

Ngam Advisors Lp increased Sumitomo Mitsui Finl Group Inc (NYSE:SMFG) stake by 53,050 shares to 1.88 million valued at $14.74M in 2017Q2. It also upped Wabtec (NYSE:WAB) stake by 8,537 shares and now owns 68,848 shares. Leucadia Natl Corp (NYSE:LUK) was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :